endometrial cancer
Oncology · 2022–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Primary advanced or recurrent endometrial cancer (both mismatch repair deficient and proficient), in combination with platinum-based chemotherapy followed by… | Jul 2025 | Not recommended | input received Medical Oncology Group |
| dostarlimab Primary advanced or first recurrent mismatch repair proficient (pMMR) endometrial cancer unsuitable for curative surgery or radiotherapy. | May 2025 | Not recommended | input received Medical Oncology Group · Inherited Cancers Australia · Rare Cancers Australia |
| durvalumab Advanced, metastatic or recurrent endometrial cancer (dMMR and pMMR populations). For dMMR EC, durvalumab in combination with platinum-based chemotherapy… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab Advanced, metastatic or recurrent endometrial cancer with disease progression following prior systemic therapy. Indicated for use in combination with… | Mar 2023 | Recommended with restriction | input received Medical Oncology Group |
| dostarlimab Recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer that has progressed on or following prior treatment with a platinum-containing… | Mar 2023 | Not recommended | input received Rare Cancers Australia |
| dostarlimab Primary advanced or first recurrent endometrial cancer in combination with platinum-containing chemotherapy (carboplatin-paclitaxel). For the dMMR population… | Nov 2023 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| dostarlimab Treatment of advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer that has progressed on or following prior treatment with a… | Mar 2022 | Not recommended | input received Medical Oncology Group |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Inherited Cancers Australia
What the PBS pays
$987M in government benefit over 2024–25, across 114,093 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| durvalumab, olaparib | $236.5M |
| dostarlimab | $10.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 5 technologies for this condition, recommending 5 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| dostarlimabDostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency | TA1117 | recommended restricted | 2025-12 |
| pembrolizumabPembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | TA1092 | recommended restricted | 2025-08 |
| dostarlimabDostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | recommended restricted | 2025-05 |
| pembrolizumabPembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | recommended | 2023-06 |
| dostarlimabDostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | recommended restricted | 2022-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.